Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Am Acad Dermatol ; 84(2): 432-470, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32738429

RESUMEN

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults.


Asunto(s)
Terapias Complementarias/métodos , Fármacos Dermatológicos/administración & dosificación , Dermatología/métodos , Psoriasis/terapia , Academias e Institutos/normas , Administración Cutánea , Terapia Combinada/métodos , Terapia Combinada/normas , Terapias Complementarias/normas , Dermatología/normas , Medicina Basada en la Evidencia/métodos , Medicina Basada en la Evidencia/normas , Fundaciones/normas , Humanos , Educación del Paciente como Asunto/normas , Psoriasis/diagnóstico , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Estados Unidos
2.
J Am Acad Dermatol ; 82(6): 1445-1486, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32119894

RESUMEN

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).


Asunto(s)
Psoriasis/tratamiento farmacológico , Acitretina/uso terapéutico , Ciclosporina/uso terapéutico , Monitoreo de Drogas , Humanos , Metotrexato/uso terapéutico , Piperidinas/uso terapéutico , Pirimidinas/uso terapéutico , Talidomida/análogos & derivados , Talidomida/uso terapéutico
3.
J Am Acad Dermatol ; 80(4): 1073-1113, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30772097
4.
J Am Acad Dermatol ; 80(4): 1029-1072, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30772098

RESUMEN

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.


Asunto(s)
Productos Biológicos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Adalimumab/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Biosimilares Farmacéuticos/uso terapéutico , Certolizumab Pegol/uso terapéutico , Quimioterapia Combinada , Etanercept/uso terapéutico , Medicina Basada en la Evidencia , Humanos , Infliximab/uso terapéutico , Piperidinas/uso terapéutico , Pirimidinas/uso terapéutico , Pirroles/uso terapéutico , Ustekinumab/uso terapéutico
5.
J Drugs Dermatol ; 13(6): 712-8, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24918562

RESUMEN

BACKGROUND: Efalizumab was voluntarily withdrawn from the market in April 2009 after four cases of progressive multifocal leukoencephalopathy. OBJECTIVE: To review the baseline characteristics and psoriasis phenotypes of patients with prior excelled response to efalizumab, and to determine the response of these patients to prior as well as subsequent therapies. By defining this subgroup of patients, particularly relating to palmoplantar psoriasis, future therapeutic considerations could be improved. DESIGN: A retrospective review of 72 patients who were on efalizumab at the time of market withdrawal was conducted. Data was obtained through chart review of patients at a specialty psoriasis clinic in Dallas, TX. MAIN OUTCOMES AND MEASURES: Patient characteristics, details of efalizumab use, and efficacy of efalizumab compared with other psoriasis treatment modalities. RESULTS: Of the 72 patients, 24 (33%) were found to have palmoplantar disease. As a group, these patients were older, more likely to be female, and less likely to have a family history of psoriasis. 48 patients (67%) were on one or more systemic and/or biologic medication prior to starting efalizumab. Their BSA improved from 5.45 to 0.8 as a group. Six patients were identified as having failed TNF alpha antagonist treatment prior to starting efalizumab. All responded well to the medication with an average BSA of 0.54. Five of these six patients had evidence of palmoplantar disease prior to starting efalizumab and five of these six patients were female. Eleven patients (15%) experienced neurologic side effects and 13 (18%) had infections while on efalizumab treatment. LIMITATIONS: This was a retrospective review. Quality of life issues could not always be fully assessed from the data available. CONCLUSIONS AND RELEVANCE: Efalizumab was effectively utilized in our clinical practice to treat patients with palmoplantar psoriasis, including six patients who had failed prior treatment with one or more TNF alpha antagonist agents.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Psoriasis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factores de Edad , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados , Femenino , Humanos , Leucoencefalopatía Multifocal Progresiva/inducido químicamente , Masculino , Persona de Mediana Edad , Psoriasis/patología , Estudios Retrospectivos , Retirada de Medicamento por Seguridad , Factores Sexuales , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA